Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial비활성화된 SARS-CoV-2 백신, BBV152의 안전성 및 면역원성: 이중 맹검, 무작위, 다기관, 2상 시험 및 이중 맹검, 무작위 1상 시험의 3개월 추적 조사의 중간 결과Clinical Trial Published on 2021-07-012022-09-12 Journal: The Lancet. Infectious Diseases [Category] Fulltext, SARS, 임상, 진단, [키워드] 1:1 95% CI Abstract addition Administered Antigen assigned baseline Bharat block blood draw cell-mediated immune response clinical trial collected defined dose double-blind Efficacy elevated elicited enrolled evaluate first dose Follow-up geometric mean GMT healthy high neutralising antibody Hindi hospital humoral inactivated India intramuscular dose investigators Local material microneutralisation test MNT multicentre neutralisation test neutralising antibody titre nine outcomes participant phase 1 trial Phase 2 study phase 2 trial Phase 3 positive Primary outcome PRNT proportion randomisation randomised Randomly reactogenicity receive Registered remained reported response Safety SARS-CoV-2 SARS-CoV-2 nucleic acid SARS-CoV-2 vaccine screened second dose second vaccination secondary outcome selected Serious Adverse Event seroconversion rate serology test significant difference significantly higher Sponsor T-cell Response Th1 phenotype the vaccine titre Toll-like receptor translation treatment group Trial Vaccine was done were assessed were excluded wild-type [DOI] 10.1016/S1473-3099(21)00070-0 PMC 바로가기 [Article Type] Clinical Trial
Effect of artificial liver blood purification treatment on the survival of critical ill COVID-19 patients인공 간 혈액 정화 치료가 코로나19 중환자 생존에 미치는 영향Multicenter Study Published on 2021-07-012022-09-11 Journal: Artificial organs [Category] SARS, 바이오마커, 치료기술, [키워드] 28-day mortality age analyzed artificial liver blood purification average average age baseline data Biochemistry block Blood Blood purification blood routine examination Case-control clinical Clinical data collected comparison control group coronavirus coronavirus disease Coronavirus disease 2019 coronavirus SARS-CoV-2 COVID-19 COVID-19 patient COVID-19 pneumonia Critical Critically ill cytokine Cytokine storm Effect enrolled IL-6 Infection Inflammatory mediators initial symptoms intensification interleukin-6 key factor Laboratory laboratory examinations liver median mediators morbidity Mortality multicenter no difference no significant difference nucleic acid open Patient persistence Pneumonia Pneumonia Severity Index Prospective Study reducing serum Serum IL-6 serum IL-6 level Severe case severe cases Sex significant difference significant increase significantly Stage survival the cytokine storm the patient therapy Treatment treatment group two group two groups Viral viral nucleic acid vital signs [DOI] 10.1111/aor.13884 PMC 바로가기 [Article Type] Multicenter Study
Tocilizumab and COVID-19: a meta-analysis of 2120 patients with severe disease and implications for clinical trial methodologiesTocilizumab 및 COVID-19: 중증 질환을 가진 2120명의 환자에 대한 메타 분석 및 임상 시험 방법론에 대한 의미Meta-Analysis Published on 2021-06-282022-09-12 Journal: Turkish Journal of Medical Sciences [Category] MERS, SARS, 진단, [키워드] 95% CI actemra benefit bioRxiv Characteristics clinical trial ClinicalTrials Cochrane Central conducted control group coronavirus COVID-19 COVID-19 patient Cytokine storm syndrome Descriptive analysis implication lower mortality material mechanical ventilation medRxiv Meta-analysis methodology Mortality outbreak Patient patients Registered Result severe disease Therapeutic benefit therapeutic benefits therapy Tocilizumab treatment group Trial trials [DOI] 10.3906/sag-2010-131 PMC 바로가기 [Article Type] Meta-Analysis
Effect of Tenofovir Disoproxil Fumarate and Emtricitabine on nasopharyngeal SARS-CoV-2 viral load burden amongst outpatients with COVID-19: A pilot, randomized, open-label phase 2 trialResearch Paper Published on 2021-06-272022-10-04 Journal: EClinicalMedicine [Category] 신약개발, 임상, [키워드] 1:1 95% CI 95% confidence interval accelerate Adverse adverse events assigned baseline clearance Cohort collected conducted COVID-19 COVID-related symptoms cycle threshold develop died drug discontinuation early treatment Effect emtricitabine Endpoint enrolled enrolment event finding France fumarate funding gastrointestinal side effect hospital hospitalisation in both groups Inclusion increase in Infection interfere IQR less median nasopharyngeal Nasopharyngeal swab Open-label Other Outpatient Patient per day phase 2 trial pilot study Randomized Randomly RdRP receive Registered reported RNA polymerase RT-PCR SARS CoV-2 SARS-COV-2 infection SARS-CoV-2 viral SARS-CoV-2 viral load secondary endpoint severe COVID-19 Standard of care Support symptom onset tenofovir therapy Time to recovery treated treatment group Trial viral burden [DOI] 10.1016/j.eclinm.2021.100993 PMC 바로가기 [Article Type] Research Paper
Glucocorticoids alone versus tocilizumab alone or glucocorticoids plus tocilizumab in patients with severe SARS-CoV-2 pneumonia and mild inflammation중증 SARS-CoV-2 폐렴 및 경증 염증이 있는 환자에서 글루코코르티코이드 단독 대 토실리주맙 단독 또는 글루코코르티코이드와 토실리주맙Case Reports Published on 2021-06-252022-09-12 Journal: Medicina clínica [Category] SARS, 임상, 진단, [키워드] Administered adverse events Clinical course Clinical outcome clinical trial COVID-19 Cytokine storm syndrome Factors Follow-up glucocorticoid ICU admission Immunosuppressive treatment Inflamación Inflammation mean hospital stay Methylprednisolone Metilprednisolona Mild moderate mortality rate Observational cohort study Patient Pneumonia retrospective Severe COVID-19 pneumonia severe SARS-CoV-2 Síndrome de tormenta de citoquinas Tocilizumab Treatment treatment group widespread [DOI] 10.1016/j.medcli.2021.01.006 PMC 바로가기 [Article Type] Case Reports
Oral nano‐curcumin formulation efficacy in the management of mild to moderate outpatient COVID‐19: A randomized triple‐blind placebo‐controlled clinical trialOriginal Research Published on 2021-06-192022-10-31 Journal: Food Science & Nutrition [Category] COVID-19, [키워드] anti‐inflammatory baseline Cell cellular signaling pathways chills clinical response clinical trial coronavirus disease Coronavirus disease 2019 cough COVID‐19 COVID‐19 patient COVID‐19 CRP Curcumin Efficacy Efficacy and safety encapsulation evaluated faster gel IMPROVE inclusion criteria inhibiting laboratory data Lymphocyte count management Mild moderate modulating oral Patient Placebo Placebo‐controlled potential treatment option protease Randomized Randomly receive reported resolved Result Sample size Serum level significantly significantly higher sore throat Symptom Treatment treatment group two groups virus were assessed [DOI] 10.1002/fsn3.2226 PMC 바로가기 [Article Type] Original Research
A multi-center phase II randomized clinical trial of losartan on symptomatic outpatients with COVID-19Research article Published on 2021-06-172022-10-05 Journal: EClinicalMedicine [Category] 임상, [키워드] 1:1 95% CI ACE2 Adverse affected all-cause hospitalization analyzed angiotensin receptor blocker ARBs Arm Biotechnology blinded Cell clinically Community contributing to COVID-19 did not reduce disease disrupting Dyspnea Effects Efficacy enrolled enzyme event event rate expected finding functional funding Genomics glomerular filtration rate hospital Hospitalization hospitalizations likelihood losartan Lung injury Mild mitigate multicenter not differ outcome Outpatient outpatients participant Participants partnership Patient Placebo placebo-controlled Primary outcome proportion RAAS Randomized randomized clinical trial RCT Replication SARS-CoV-2 virus secondary significantly statistically Support supported symptom onset symptomatic symptomatic COVID-19 disease temperature treat Treatment treatment group Trial viral entry Viral load was reduced were blinded with COVID-19 [DOI] 10.1016/j.eclinm.2021.100957 [Article Type] Research article
Combination of (interferon beta-1b, lopinavir/ritonavir and ribavirin) versus favipiravir in hospitalized patients with non-critical COVID-19: A cohort study비 임계 CovID-19를 가진 입원 환자에서 (인터페론 베타 -1B, 로피 나비르/리토 나비르 및 리바비린) 대 Favipiravir의 조합 : 코호트 연구Comparative Study Published on 2021-06-102022-09-10 Journal: PLoS ONE [Category] SARS, 치료제, [키워드] (Lopinavir/ritonavir 28-day mortality adjusted hazard ratio allocation antiviral therapy association change Cohort cohort study confounders Corticosteroids covariate COVID-19 Cox regression model diarrhea disease severity Efficacy and safety examined Favipiravir FPV groups Hospitalization hospitalized COVID-19 patients hospitalized patient hospitalized patients IFN interferon Interferon beta-1b less Lopinavir Lopinavir/ritonavir median Mortality National national treatment nausea objective observational study patients required Result ribavirin Ritonavir study cohort symptoms onset systemic corticosteroid systemic corticosteroids therapy treated Treatment treatment group Treatment protocol [DOI] 10.1371/journal.pone.0252984 PMC 바로가기 [Article Type] Comparative Study
Hydroxychloroquine plus standard of care compared with standard of care alone in COVID-19: a meta-analysis of randomized controlled trialsCOVID-19에서 표준 치료와 비교한 하이드록시클로로퀸과 표준 치료: 무작위 대조 시험의 메타 분석Meta-Analysis Published on 2021-06-072022-09-10 Journal: Scientific Reports [Category] SARS, 임상, 치료법, 치료제, [키워드] 95% CI 95% confidence interval addition adverse event adverse events all-cause mortality benefit body temperature Chain Reaction clinical clinical trials Cochrane Library collaboration controlled trials coronavirus coronavirus disease COVID-19 database Disease progression Efficacy and safety eligible evaluated HCQ Hospital stay hospitalized patient hospitalized patients Hydroxychloroquine identify mechanical ventilation Medical research medRxiv Meta-analysis no significant differences Outcomes research Patient PCR polymerase chain polymerase chain reaction Randomized controlled trial Recovery time resources risk ratio searched significant difference significant differences Standard of care systematic review Treatment treatment group two group two groups Version was performed Web with COVID-19 [DOI] 10.1038/s41598-021-91089-3 PMC 바로가기 [Article Type] Meta-Analysis
A randomized and comparative study to assess safety and efficacy of supplemental treatment of a herbal formulation – Aayudh Advance comprising essential oils in patients with corona virus 2019 (COVID-19)Research article Published on 2021-06-012022-10-05 Journal: Contemporary Clinical Trials Communications [Category] 치료법, [키워드] Aayudh advance advance Adverse Adverse drug reaction Arm ARMS assigned biochemical body temperature breath clinical Clinical improvement Clinical sign Control Corona Covariate adaptive randomization COVID-19 COVID-19 negative COVID-19 patients CRP Ct value diagnosed discharge drug interaction E gene E-gene effective Efficacy enrolled exclusion criteria Herbal hospital in viral Inclusion indicated Mild NLR objective Patient protocol Randomized reaction reduction reported Result RT-PCR Safe Scoring Serum ferritin significant increase Standard Standard of care (SOC) statistically significant reduction Symptom symptomatic symptomatic patient Test the patient Total Treatment treatment group Viral load virus were recorded withdrawn [DOI] 10.1016/j.conctc.2021.100755 [Article Type] Research article